Repurposing-a ray of hope in tackling extensively drug resistance in tuberculosis

International Journal of Infectious Diseases

Volumn 32, Issue , 2015, Pages 50-55

  Maitra, Arundhati ^a   Bates, Sadé ^a   Kolvekar, Trupti ^a   Devarajan, Padma V ^b   Guzman, Juan D ^c   Bhakta, Sanjib ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^c UNIVERSIDAD DEL NORTE   (Colombia)

Author keywords

Antibiotic resistance; Mycobacterium tuberculosis; Repositioning; Repurposing; Tuberculosis (TB); Whole cell phenotypic screening

Indexed keywords

AVERMECTIN DERIVATIVE; BETA LACTAM ANTIBIOTIC; CALCITRIOL; CARBAPENEM; CLAVULANIC ACID; CLOFAZIMINE; DELAMANID; DISULFIRAM; ENTACAPONE; LINEZOLID; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; NITAZOXANIDE; NITROIMIDAZOFURAN DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PRETOMANID; PYRAZINAMIDE; QUINOLONE DERIVATIVE; SUTEZOLID; TEBIPENEM; THIORIDAZINE; TOLCAPONE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; VITAMIN D;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CROSS RESISTANCE; DRUG EFFICACY; DRUG REPOSITIONING; DRUG TARGETING; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; MEDICATION COMPLIANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; STRUCTURE ACTIVITY RELATION; DRUG EFFECTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG REPOSITIONING; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MYCOBACTERIUM TUBERCULOSIS;

EID: 84925251163     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2014.12.031     Document Type: Article

References (81)

1. Pawlowski A., Jansson M., Sköld M., Rottenberg M.E., Källenius G. Tuberculosis and HIV co-infection. PLoS Pathog 2012, 8:e1002464.
2. Dorman S.E., Chaisson R.E. From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis. Nat Med 2007, 13:295-298.
3. Gandhi N.R., Nunn P., Dheda K., Schaaf H.S., Zignol M., van Soolingen D., et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010, 375:1830-1843.
4. Lonnroth K., Jaramillo E., Williams B.G., Dye C., Raviglione M. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med 2009, 68:2240-2246.
5. Almeida Da Silva P.E., Palomino J.C. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother 2011, 66:1417-1430.
6. Gupta A., Kaul A., Tsolaki A.G., Kishore U., Bhakta S. Mycobacterium tuberculosis: immune evasion, latency and reactivation. Immunobiology 2012, 217:363-374.
7. Jindani A., Aber V., Edwards E., Mitchison D. The early bactericidal activity of drugs on patients with pulmonary tuberculosis. Am Rev Respir Dis 1980, 121:939-949.
8. Dick T. Dormant tubercle bacilli: the key to more effective TB chemotherapy?. J Antimicrob Chemother 2001, 47:117-118.
9. Coates A.R., Halls G., Hu Y. Novel classes of antibiotics or more of the same?. Br J Pharmacol 2011, 163:184-194.
10. Hay M., Thomas D.W., Craighead J.L., Economides C., Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol 2014, 32:40-51.
11. Finsterer J., Frank M. Repurposed drugs in metabolic disorders. Curr Top Med Chem 2013, 13:2386-2394.
12. Calabrese L., Fleischer A.B. Thalidomide: current and potential clinical applications. Am J Med 2000, 108:487-495.
13. Moreland R.B., Goldstein I., Traish A. Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells. Life Sci 1998, 62:PL309-PL318.
14. Maiga M., Agarwal N., Ammerman N.C., Gupta R., Guo H., Maiga M.C., et al. Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model. PLoS One 2012, 7:e30749.
15. Languillon J. The effects of thalidomide on leprosy reaction. Intl J Leprosy 1971, 39:590-592.
16. Schoeman J.F., Fieggen G., Seller N., Mendelson M., Hartzenberg B. Intractable intracranial tuberculous infection responsive to thalidomide: report of four cases. J Child Neurol 2006, 21:301-308.
17. Palomino J.C., Martin A. Is repositioning of drugs a viable alternative in the treatment of tuberculosis?. J Antimicrob Chemother 2013, 68:275-283.
18. Zumla A., Nahid P., Cole S.T. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 2013, 12:388-404.
19. Drlica K., Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 1997, 61:377-392.
20. Gillespie S.H., Billington O. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother 1999, 44:393-395.
21. Miyazaki E., Miyazaki M., Chen J.M., Chaisson R.E., Bishai W.R. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother 1999, 43:85-89.
22. Moadebi S., Harder C.K., Fitzgerald M.J., Elwood K.R., Marra F. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 2007, 67:2077-2099.
23. Gosling R.D., Uiso L.O., Sam N.E., Bongard E., Kanduma E.G., Nyindo M., et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2003, 168:1342-1345.
24. Gillespie S.H., Crook A.M., McHugh T.D., Mendel C.M., Meredith S.K., Murray S.R., et al. Consortium REMoxTB. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014, 371:1577-1587.
25. Gatifloxacin. Tuberculosis 2008, 88:109-111. TBAlliance.
26. Moxifloxacin. Tuberculosis 2008, 88:127-131. TBAlliance.
27. Bozeman L., Burman W., Metchock B., Welch L., Weiner M. Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada. Clin Infect Dis 2005, 40:386-391.
28. Ginsburg A.S., Grosset J.H., Bishai W.R. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003, 3:432-442.
29. Ginsburg A.S., Woolwine S.C., Hooper N., Benjamin W.H., Bishai W.R., Dorman S.E., et al. The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med 2003, 349:1977-1978.
30. Hu Y., Coates A.R., Mitchison D.A. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003, 47:653-657.
31. Kam K.M., Yip C.W., Cheung T.L., Tang H.S., Leung O.C., Chan M.Y. Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility. Microb Drug Resist 2006, 12:7-11.
32. Stover C.K., Warrener P., VanDevanter D.R., Sherman D.R., Arain T.M., Langhorne M.H., et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000, 405:962-966.
33. Ashtekar D.R., Costa-Perira R., Nagrajan K., Vishvanathan N., Bhatt A.D., Rittel W. In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1993, 37:183-186.
34. Mukherjee T., Boshoff H. Nitroimidazoles for the treatment of TB: past, present and future. Future Med Chem 2011, 3:1427-1454.
35. Lin P.L., Dartois V., Johnston P.J., Janssen C., Via L., Goodwin M.B., et al. Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc Natl Acad Sci U S A 2012, 109:14188-14193.
36. Hugonnet J.E., Blanchard J.S. Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate. Biochemistry 2007, 46:11998-12004.
37. Horita Y., Maeda S., Kazumi Y., Doi N. In vitro susceptibility of Mycobacterium tuberculosis isolates to an oral carbapenem alone or in combination with beta-lactamase inhibitors. Antimicrob Agents Chemother 2014, 58:7010-7014.
38. England K., Boshoff H.I., Arora K., Weiner D., Dayao E., Schimel D., et al. Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother 2012, 56:3384-3387.
39. Payen M.C., De Wit S., Martin C., Sergysels R., Muylle I., Van Laethem Y., et al. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis [Case study]. Int J Tuberc Lung Dis 2012, 16:558-560.
40. Kato K., Shirasaka Y., Kuraoka E., Kikuchi A., Iguchi M., Suzuki H., et al. Intestinal absorption mechanism of tebipenem pivoxil, a novel oral carbapenem: involvement of human OATP family in apical membrane transport. Mol Pharm 2010, 7:1747-1756.
41. Horita Y., Maeda S., Kazumi Y., Doi N. In vitro susceptibility of Mycobacterium tuberculosis isolates to an oral carbapenem alone or in combination with β-lactamase inhibitors. Antimicrob Agents Chemother 2014, 58:7010-7014.
42. De Lorenzo S., Alffenaar J.W., Sotgiu G., Centis R., D'Ambrosio L., Tiberi S., et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2013, 41:1386-1392.
43. Zhao W., Guo Z., Zheng M., Zhang J., Wang B., Li P., et al. Activity of linezolid-containing regimens against multidrug-resistant tuberculosis in mice. Int J Antimicrob Agents 2014, 43:148-153.
44. Yang C., Lei H., Wang D., Meng X., He J., Tong A., et al. In vitro activity of linezolid against clinical isolates of Mycobacterium tuberculosis, including multidrug-resistant and extensively drug-resistant strains from Beijing, China. Jpn J Infect Dis 2012, 65:240-242.
45. Fortún J., Martín-Dávila P., Navas E., Pérez-Elías M.J., Cobo J., Tato M., et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005, 56:180-185.
46. Kloss P., Xiong L., Shinabarger D.L., Mankin A.S. Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. J Mol Biol 1999, 294:93-101.
47. Wallis R.S., Dawson R., Friedrich S.O., Venter A., Paige D., Zhu T., et al. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PLoS One 2014, 9:e94462.
48. De Logu A., Onnis V., Saddi B., Congiu C., Schivo M.L., Cocco M.T. Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis. J Antimicrob Chemother 2002, 49:275-282.
49. Cholo M.C., Steel H.C., Fourie P.B., Germishuizen W.A., Anderson R. Clofazimine: current status and future prospects. J Antimicrob Chemother 2012, 67:290-298.
50. Nzila A., Ma Z., Chibale K. Drug repositioning in the treatment of malaria and TB. Future Med Chem 2011, 3:1413-1426.
51. Reddy V.M., O'Sullivan J.F., Gangadharam P.R. Antimycobacterial activities of riminophenazines. J Antimicrob Chemother 1999, 43:615-623.
52. Van Deun A., Maug A.K., Salim M.A., Das P.K., Sarker M.R., Daru P., et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010, 182:684-692.
53. Dey T., Brigden G., Cox H., Shubber Z., Cooke G., Ford N. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2013, 68:284-293.
54. Gopal M., Padayatchi N., Metcalfe J., O'Donnell M. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis 2013, 17:1001.
55. Lim L.E., Vilcheze C., Ng C., Jacobs W.R., Ramon-Garcia S., Thompson C.J. Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant clinical strains. Antimicrob Agents Chemother 2013, 57:1040-1046.
56. Muhammed Ameen S., Drancourt M. Ivermectin lacks antituberculous activity. J Antimicrob Chemother 2013, 68:1936-1937.
57. Lougheed K.E., Taylor D.L., Osborne S.A., Bryans J.S., Buxton R.S. New anti-tuberculosis agents amongst known drugs. Tuberculosis (Edinb) 2009, 89:364-370.
58. Sheth U.K. Mechanisms of anthelmintic action. Prog Drug Res 1975, 19:147-157.
59. Abboud P., Lemee V., Gargala G., Brasseur P., Ballet J.J., Borsa-Lebas F., et al. Successful treatment of metronidazole- and albendazole-resistant giardiasis with nitazoxanide in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2001, 32:1792-1794.
60. de Carvalho L.P., Lin G., Jiang X., Nathan C. Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance. J Med Chem 2009, 52:5789-5792.
61. Shigyo K., Ocheretina O., Merveille Y.M., Johnson W.D., Pape J.W., Nathan C.F., et al. Efficacy of nitazoxanide against clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2013, 57:2834-2837.
62. Kinnings S.L., Liu N., Buchmeier N., Tonge P.J., Xie L., Bourne P.E. Drug discovery using chemical systems biology: repositioning the safe medicine comtan to treat multi-drug and extensively drug resistant tuberculosis. PLoS Comput Biol 2009, 5:e1000423.
63. Amaral L., Kristiansen J.E., Abebe L.S., Millett W. Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis. J Antimicrob Chemother 1996, 38:1049-1053.
64. Ordway D., Viveiros M., Leandro C., Bettencourt R., Almeida J., Martins M., et al. Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003, 47:917-922.
65. van Soolingen D., Hernandez-Pando R., Orozco H., Aguilar D., Magis-Escurra C., Amaral L., et al. The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. PLoS One 2010, 5:e12640.
66. Weinstein E.A., Yano T., Li L.S., Avarbock D., Avarbock A., Helm D., et al. Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs. Proc Natl Acad Sci U S A 2005, 102:4548-4553.
67. Amaral L., Viveiros M. Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections. Int J Antimicrob Agents 2012, 39:376-380.
68. Amaral L., Boeree M.J., Gillespie S.H., Udwadia Z.F., van Soolingen D. Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int J Antimicrob Agents 2010, 35:524-526.
69. Thioridazine. Tuberculosis 2008, 88:164-167. TBAlliance.
70. Fuller R.K., Gordis E. Does disulfiram have a role in alcoholism treatment today?. Addiction 2004, 99:21-24.
71. Horita Y., Takii T., Yagi T., Ogawa K., Fujiwara N., Inagaki E., et al. Anti-tubercular activity of disulfiram, an anti-alcoholism drug, against multi-drug and extensively drug-resistant Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2012, 56:4140-4145.
72. Liu P.T., Stenger S., Tang D.H., Modlin R.L. Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol 2007, 179:2060-2063.
73. Liu P.T., Stenger S., Li H., Wenzel L., Tan B.H., Krutzik S.R., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311:1770-1773.
74. Martineau A.R., Timms P.M., Bothamley G.H., Hanifa Y., Islam K., Claxton A.P., et al. High-dose vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 2011, 377:242-250.
75. Guzman J.D., Evangelopoulos D., Gupta A., Birchall K., Mwaigwisya S., Saxty B., et al. Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay. BMJ Open 2013, 3:e002672-e2685.
76. Gold B., Pingle M., Brickner S.J., Shah N., Roberts J., Rundell M., et al. Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials. Proc Natl Acad Sci U S A 2012, 109:16004-16011.
77. Yin Z., Wang Y., Whittell L.R., Jergic S., Liu M., Harry E., et al. DNA replication is the target for the antibacterial effects of nonsteroidal anti-inflammatory drugs. Chem Biol 2014, 21:481-487.
78. Canan C.H., Gokhale N.S., Carruthers B., Lafuse W.P., Schlesinger L.S., Torrelles J.B., et al. Characterization of lung inflammation and its impact on macrophage function in aging. J Leukoc Biol 2014, 96:473-480.
79. Collins L., Franzblau S.G. Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother 1997, 41:1004-1009.
80. Evangelopoulos D., Bhakta S. Rapid methods for testing inhibitors of mycobacterial growth. Antibiotic resistance protocols. Springer; 2010, 193-201.
81. Gupta A., Bhakta S. An integrated surrogate model for screening of drugs against Mycobacterium tuberculosis. J Antimicrob Chemother 2012, 67:1380-1391.